Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets

Ronald de Wit(Erasmus MC Cancer Institute), Jaap Verweij(Deutz (Germany)), Olaf van Tellingen(Dutch Cancer Society), M de Boer-Dennert(Erasmus MC Cancer Institute), J. H. Beijnen(Erasmus MC Cancer Institute), JHM Schellens(Erasmus MC Cancer Institute)
British Journal of Cancer
July 1, 1996
10.1038/bjc.1996.361
Cited by 12

Related Papers

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Cremophor EL
|European Journal of Cancer|2001|1.6k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k